Revista: BMC Health Services Research
Resumen: There is evidence suggesting that most thromboembolic complications could be prevented with adequate pharmacological anticoagulation. We estimated the direct health care costs of anticoagulant treatment with oral vitamin K antagonists in patients diagnosed with non-valvular atrial fibrillation. We collected data from 1,257 patients diagnosed with non-valvular atrial fibrillation who were receiving oral anticoagulant therapy. Depending on the scheme used, the direct health care costs for these patients ranged from €423,695 − €1,436,038 per annum. The average cost per patient varied between €392 − €1,341, depending on the approach used. Patients with international normalized ratio values within the therapeutic range on 25% of their visits represented an average cost between €441.70 − €1,592. Those within the therapeutic range on 25%–50% of visits had associated costs of €512.37 − €1,703.91. When international normalized ratio values were within the therapeutic range on 50% − 75% of the visits, the costs ranged between €400.80− €1,375.74. The average cost was €305.23 − €1,049.84 when the values were within the therapeutic range for over 75% of visits.
Cómo citar: Hidalgo-Vega, Á., Askari, E., Vidal, R., Aranda-Reneo, I., Gonzalez-Dominguez, A., Ivanova, A., … & Llamas, P. (2014). Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation. BMC health services research, 14(1), 46.